Skip to main content
HHS Logo U.S. Department of Health & Human Services NIH logo National Institutes of Health

Bridging Interventional Development Gaps (BrIDGs)

About BrIDGs

Find out more about the BrIDGs program and its role in advancing new therapeutics.

Scientific Capabilities

BrIDGs offers state-of-the-art expertise and resources for preclinical development.

BrIDGs Projects

Explore active and completed preclinical development projects supported by BrIDGs.

Facebook icon.

About BrIDGs

Find out more about the BrIDGs program and its role in advancing new therapeutics.

Scientific Capabilities

BrIDGs offers state-of-the-art expertise and resources for preclinical development.

Facebook icon.

BrIDGs Projects

Explore active and completed preclinical development projects supported by BrIDGs.

Work with Us

BrIDGs forms partnerships with researchers from academia, nonprofit organizations and pharmaceutical and biotechnology companies to complete preclinical development for promising therapeutic candidates. Learn more and contact BrIDGs.

Why BrIDGs Matters

As of fall 2015, BrIDGs has generated data to support 18 IND applications that have been cleared by the Food and Drug Administration and one clinical trial application cleared by Health Canada. A total of 14 projects have been evaluated in clinical trials. Five BrIDGs-supported agents have been evaluated in Phase II human clinical trials, in which researchers give an experimental therapy to a group of patients to evaluate the effectiveness and safety of a treatment. Third-party organizations have licensed or invested in 10 agents during or after their development by BrIDGs. Learn more about BrIDGs projects.

Thinking about applying?

Review information for applicants.